FDA OKs Emergency Use of Bamlanivimab for COVID-19
The EUA was authorized based on data from the ongoing randomized, double-blind, placebo-controlled phase 2 BLAZE-1 study.
Infectious Disease
Infections Common in Glomerular Disease Population
Investigators identify risks factors for infection-related acute care events in children and adults with glomerular disease.
Convalescent Plasma Has Limited Benefit for Moderate COVID-19
Randomized phase II trial shows no drop in progression to severe disease, all-cause deaths.
Trial of Antibody Drug for COVID-19 Stopped for Lack of Effectiveness
Eli Lilly says government is continuing a separate study testing the antibody drug in mild to moderately ill patients.
Factors ID’d for Strong Antibody Response in COVID-19
Increased antibody responses associated with male sex, older age, hospitalizations for COVID-19.
FDA Approves Veklury as First Treatment for COVID-19
The FDA approved Veklury (remdesivir; Gilead Sciences) for the treatment of COVID-19 in patients aged ≥12 years (weighing ≥40kg) requiring hospitalization.
COVID-19 Outcomes Worse in Waitlisted Kidney Failure Patients vs KTRs
COVID-19 is associated with higher hospitalization and death rates among patients with end-stage kidney disease on a kidney transplant waitlist compared with kidney transplant recipients.
AKI Risk Is High Among HIV-Positive Patients Hospitalized With COVID-19
Acute kidney injury developed in more than half of patients with HIV who were hospitalized with COVID-19 at a medical center in Bronx, New York.
High Death Rate Reported for KTRs Hospitalized With COVID-19
Among 145 kidney transplant patients hospitalized at 11 transplant centers, 30% died at a median of 10 days after admission, a study found.
AKI Increases Death Risk Among COVID-19 Patients
Patients infected with SARS-CoV-2 appear to have a lower incidence of AKI compared with patients infected with Middle East respiratory syndrome coronavirus (MERS-CoV).
-
Loading...
-
Loading...
Next post in Kidney Week 2020 Reimagined
